Skip To Main Content
Zhekai Ying on Muck Rack

Zhekai Ying

As seen in: Frontiers in Immunology, Taylor & Francis Online
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Zhekai

Contact Zhekai, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Drug-associated inflammatory bowel disease: a real-world pharmacovigilance study using the FAERS and JADER databases

|
By Yuou Ying, Mengyuan Shen, Jinhan Chen, Tongfei Feng, Zhekai Ying, DongDong Yang, Ruyi Ju, Jiannong Wu, Zejiong Li
| Frontiers in Immunology
Abstract Background: Although several medications have been linked to inflammatory bowel disease (IBD), the association between most drugs and IBD remains unclear. This study aimed to identify medications most frequently reported in connection with IBD by analyzing large-scale data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) and the Japan Adverse Drug Event Report (JADER) database.
Open in Who Shared Issue with article?

Impact of complement C3 levels on the development of healthcare-associated infections in intensive care patients: a retrospective case-control study

|
By Chenjuan Wang, Binhao Chen, Mengyuan Shen, Zhekai Ying
| Taylor & Francis Online
Abstract Purpose The immune system serves as a critical line of defence against pathogenic microorganisms. To investigate the impact of immune markers, measured within the first 48 h of intensive care unit (ICU) admission, on the incidence of healthcare-associated infections (HAIs) in ICU patients. Methods This case-control study included 364 patients admitted from 1 January 2020 to 30 November 2023, receiving immune marker testing within 48 h of ICU admission.
Open in Who Shared Issue with article?
See all 2 articles